Related Experiment Video
Updated: May 28, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
[Nephroprotection, fact or fiction?]
Thierry Krummel1, Anne-Laure Faller, Dorothée Bazin
1Hôpitaux universitaires de Strasbourg, service de néphrologie, 67792 Strasbourg cedex, France. thierry.krummel@chru-strasbourg.fr
Abstract:
Clinical studies of the last 15 years have shown the benefit of pharmacological interventions on the progression of chronic kidney disease, confirming the concept of nephroprotection. Pharmacological blockade of the renin angiotensin system remains the cornerstone of the nephroprotective treatment but the benefits and limitations are now better defined. The RAS blockers are all the more efficient than the proteinuria is abundant and nephroprotection is obtained in proportion to the reduction in proteinuria. Combinations of ACEI+ARA are not validated and their use should be considered only under the supervision of a specialist when optimal monotherapy has failed. The target blood pressure has been the subject of recent controversies, particularly in type 2 diabetic patients with nephropathy. The target should be individualized based on the main risk, renal or cardiovascular. Recent maneuvers have also shown a nephroprotective effect, including the correction of metabolic acidosis with sodium bicarbonate.
Insights
Pharmacological interventions slow chronic kidney disease progression, with renin-angiotensin system blockers being key. Nephroprotection is linked to reduced proteinuria and individualized blood pressure targets.
Area of Science:
- Nephrology
- Pharmacology
Context:
- Recent clinical studies highlight pharmacological interventions for chronic kidney disease (CKD) management.
- The concept of nephroprotection is established, emphasizing slowing disease progression.
Purpose:
- To review the benefits and limitations of pharmacological interventions in CKD.
- To discuss the role of renin-angiotensin system (RAS) blockers and blood pressure targets in nephroprotection.
Summary:
- Renin-angiotensin system blockers are central to nephroprotective strategies, with efficacy correlating to proteinuria reduction.
- Combination therapy with ACE inhibitors (ACEI) and angiotensin II receptor antagonists (ARA) is not routinely recommended.
- Individualized blood pressure targets are crucial, especially in type 2 diabetic nephropathy, balancing renal and cardiovascular risks.
- Correction of metabolic acidosis with sodium bicarbonate also demonstrates nephroprotective effects.
Impact:
- Provides an updated overview of evidence-based nephroprotective treatments.
- Informs clinical practice regarding RAS blockade, combination therapies, and blood pressure management in CKD.
- Highlights emerging nephroprotective strategies like metabolic acidosis correction.
More Related Videos
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Nephrotic Syndrome I : Introduction
Chronic Kidney Disease III: Interprofessional Care
Diabetic Nephropathy
Acute Kidney Injury V: Interprofessional Care
Nephrotic Syndrome II : Assessment and Medical Management

